Lilly Humulin package label must designate Novo Nordisk's NovoPen trademarks, court rules.
Executive Summary
LILLY HUMULIN (HUMAN INSULIN) PACKAGE LABEL WILL BE MODIFIED to indicate that the NovoPen and NovolinPen trademarks referred to on the label are registered trademarks of Novo Nordisk, under a court order handed down by the U.S. District Court for the Southern District of New York. Lilly is "enjoined from distributing to wholesalers Humulin insulin cartridges in their current packaging which does not attribute ownership of" Novo Nordisk's trademarks, the Aug. 30 order states. The injunction does not effect products already shipped to wholesalers or retailers.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth